Karyopharm The…

Karyopharm Therapeutics financials

View Company

Summary - Funding Rounds

Founding Date

2008

Total Funding

$248.7 m

Investors

Delphi Ventures, New Leaf Venture Partners, Foresite Capital
Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

387.0k229.0k250.0k

Revenue growth, %

(41%)9%

R&D expense

28.5m60.1m97.7m86.9m107.3m

General and administrative expense

5.9m15.9m21.6m23.9m24.9m

Operating expense total

34.3m76.1m119.3m110.9m132.1m

EBIT

(33.9m)(75.8m)(119.1m)(110.7m)(130.5m)

EBIT margin, %

(8773%)(33121%)(47630%)

Interest expense

1.0k

Interest income

3.0k97.0k897.0k1.3m1.7m

Pre tax profit

(109.4m)(128.9m)

Income tax expense

(139.0k)(63.0k)

Net Income

(33.9m)(75.8m)(118.2m)(109.6m)(129.0m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

7.7mwdxefcqufszuzezftuxetqsqxt11.0m13.2m16.0m20.8m27.0m25.9m21.8m24.6m19.9m24.1m23.1m25.2m41.3m86.1m

General and administrative expense

1.6m2.9m3.3m3.8m5.4m6.2m4.8m5.6m6.0m5.9m6.3m6.6m5.8m7.6m17.1m

Operating expense total

9.3m13.9m16.5m19.8m26.2m33.2m30.7m27.3m30.5m25.8m30.3m29.8m31.1m48.9m103.2m

EBIT

(9.3m)(13.7m)(16.4m)(19.7m)(26.1m)(33.0m)(30.6m)(27.3m)(30.5m)(25.7m)(30.3m)(29.8m)(31.1m)(38.9m)(73.3m)

Interest expense

18.0k

Interest income

18.0k17.0k20.0k141.0k267.0k239.0k286.0k329.0k311.0k400.0k412.0k454.0k509.0k1.2m

Pre tax profit

(29.9m)(29.4m)(30.6m)(38.4m)(72.1m)

Income tax expense

(23.0k)(18.0k)(13.0k)(12.0k)5.0k

Net Income

(9.3m)(13.7m)(16.4m)(19.7m)(26.1m)(32.7m)(30.4m)(27.1m)(30.2m)(25.4m)(29.9m)(29.4m)(30.6m)(38.5m)(72.1m)

Karyopharm Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

156.0m150.6m58.4m49.7m69.0m

Accounts Receivable

Inventories

2.0m2.0m2.0m2.1m

Current Assets

158.0m207.8m177.6m131.6m148.4m

PP&E

240.0k2.8m3.5m2.8m2.2m

Total Assets

158.2m220.3m215.4m180.4m180.3m

Accounts Payable

1.7m6.3m3.8m4.8m5.7m

Short-term debt

Current Liabilities

3.3m12.3m15.1m16.5m49.5m

Long-term debt

Total Debt

Total Liabilities

17.1m18.1m50.8m

Additional Paid-in Capital

217.5m345.2m455.2m528.6m625.0m

Retained Earnings

(138.3m)(256.5m)(366.1m)(495.3m)

Total Equity

154.9m206.8m198.4m162.2m129.5m

Financial Leverage

1 x1.1 x1.1 x1.1 x1.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

52.9m144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m

Current Assets

53.6m147.6m135.3m231.3m249.3m225.3m198.3m138.1m124.2m130.3m112.2m145.7m121.7m133.3m244.6m

PP&E

246.0k322.0k604.0k2.7m3.3m3.2m3.7m3.3m3.2m3.0m2.7m2.5m2.3m2.5m2.6m

Total Assets

55.9m149.3m137.7m235.2m292.0m263.3m237.0m192.1m170.9m183.6m155.4m185.8m163.8m146.4m256.6m

Accounts Payable

1.7m3.3m3.5m2.1m7.0m4.5m4.6m4.1m4.1m2.2m4.2m3.2m1.9m4.9m3.8m

Current Liabilities

4.0m5.0m5.6m6.2m14.7m14.1m14.4m13.2m15.5m15.0m15.5m17.5m21.2m46.7m36.5m

Total Liabilities

6.0m7.4m16.5m16.0m16.4m15.1m17.3m16.7m17.1m19.0m22.6m50.8m43.1m

Additional Paid-in Capital

2.6m220.4m224.4m340.2m439.9m444.6m448.1m460.5m467.2m506.1m534.8m592.5m597.6m629.6m781.2m

Retained Earnings

(92.7m)(112.4m)(164.4m)(197.1m)(227.5m)(283.6m)(313.7m)(339.2m)(396.3m)(425.7m)(456.3m)(533.8m)(567.5m)

Total Equity

(47.8m)144.1m131.7m227.8m275.5m247.3m220.6m177.0m153.6m166.9m138.4m166.7m141.2m95.5m213.5m

Financial Leverage

-1.2 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.5 x1.2 x

Karyopharm Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(33.9m)(75.8m)(118.2m)(109.6m)(129.0m)

Depreciation and Amortization

144.0k323.0k634.0k717.0k713.0k

Accounts Receivable

Inventories

(1.4m)(45.0k)(55.0k)(120.0k)

Accounts Payable

664.0k4.5m(2.4m)945.0k909.0k

Cash From Operating Activities

(30.3m)(51.4m)(94.0m)(84.4m)(73.7m)

Purchases of PP&E

(57.0k)(2.8m)(1.4m)(70.0k)(62.0k)

Cash From Investing Activities

(57.0k)(67.0m)(90.8m)24.6m17.1m

Cash From Financing Activities

185.9m113.1m92.7m51.2m75.7m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(21.8m)(13.7m)(30.1m)(49.8m)(26.1m)(58.8m)(30.4m)(27.1m)(30.2m)(82.6m)(29.9m)(59.3m)(89.9m)(38.5m)(72.1m)

Depreciation and Amortization

106.0k85.0k191.0k292.0k537.0k363.0k539.0k169.0k353.0k

Accounts Payable

673.0k1.7m362.0k7.0m(1.8m)4.6m4.1m4.1m(1.7m)4.2m(1.5m)(2.9m)(773.0k)(1.9m)

Cash From Operating Activities

(20.2m)(22.5m)(38.7m)(48.3m)(64.4m)(46.4m)(68.2m)(34.7m)(72.3m)

Purchases of PP&E

(25.0k)(449.0k)(2.7m)(774.0k)(45.0k)(7.0k)(382.0k)(779.0k)

Cash From Investing Activities

(25.0k)(849.0k)(3.1m)(169.2m)18.0m(585.0k)20.0m2.5m(25.1m)

Cash From Financing Activities

72.8m(367.0k)113.0m91.2m31.9m52.6m52.8m429.0k147.6m
Download Excel
Report incorrect company information

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10
Download Excel
Report incorrect company information

Karyopharm Therapeutics Employee Rating

2.919 votes
Culture & Values
3.2
Work/Life Balance
2.2
Senior Management
2.9
Salary & Benefits
3.9
Career Opportunities
3.4
Source
View Karyopharm Therapeutics profile

Competitors

Provectus Biopharmaceuticals
Healthcare - Public
Exelixis
Healthcare - Public
Genocea Biosciences
Healthcare - Public
Inspyr Therapeutics
Healthcare - Public
Compare competitors